Shelanski, Michael L.

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,901

Primary age-related tauopathy (PART): a common pathology associated with human aging

Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,467

Primary Care Outcomes in Patients Treated by Nurse Practitioners or Physicians: A Randomized Trial

Mundinger, M. O., Kane, R. L., Lenz, E. R., Totten, A. M., Tsai, W.-Y., Cleary, P. D., Friedewald, W. T., Siu, A. L., & Shelanski, M. L. (2000) · JAMA

Nursing Roles and PracticesPrimary Care and Health Outcomes

Cited by 955

Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease

Mayeux, R., Ottman, R., Maestre, G., Ngai, C., Tang, M.-X., Ginsberg, H., Chun, M., Tycko, B., & Shelanski, M. (1995) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 590

Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling

Vitolo, O. V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O., & Shelanski, M. (2002) · Proceedings of the National Academy of Sciences

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 534

Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment

Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 442

Dendrite and dendritic spine alterations in alzheimer models

Moolman, D. L., Vitolo, O. V., Vonsattel, J.-P. G., & Shelanski, M. L. (2004) · Journal of Neurocytology

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 245

Reversal of long-term dendritic spine alterations in Alzheimer disease models

Smith, D. L., Pozueta, J., Gong, B., Arancio, O., & Shelanski, M. (2009) · Proceedings of the National Academy of Sciences

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 229

Specific Downregulation of Hippocampal ATF4 Reveals a Necessary Role in Synaptic Plasticity and Memory

Pasini, S., Corona, C., Liu, J., Greene, L. A., & Shelanski, M. L. (2015) · Cell Reports

Memory and Neural MechanismsNeuroscience and Neuropharmacology Research

Cited by 116

Assembly and Interrogation of Alzheimer’s Disease Genetic Networks Reveal Novel Regulators of Progression

Aubry, S., Shin, W., Crary, J. F., Lefort, R., Qureshi, Y. H., Lefebvre, C., Califano, A., & Shelanski, M. L. (2015) · PLOS ONE

Alzheimer's disease research and treatmentsBioinformatics and Genomic Networks

Cited by 106

τ Regulation of Microtubule‐Microtubule Spacing and Bundling

Frappier, T. F., Georgieff, I. S., Brown, K., & Shelanski, M. L. (1994) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsMicrotubule and mitosis dynamics

Cited by 53

Generation of iPSC lines from archived non-cryoprotected biobanked dura mater

Sproul, A. A., Vensand, L. B., Dusenberry, C. R., Jacob, S., Vonsattel, J. P. G., Paull, D. J., Shelanski, M. L., Crary, J. F., & Noggle, S. A. (2014) · Acta Neuropathologica Communications

Pluripotent Stem Cells ResearchNeurogenesis and neuroplasticity mechanisms

Cited by 27